🟢 ACADIA Pharmaceuticals is trading 4% up today after UBS raised its price target to $49

ACADIA Pharmaceuticals is trading 4.03% up now at $30.18 after UBS raised its price target to $49 from $45 while reiterating a Buy rating.

• UBS cited increased optimism around remlifanserin and its Alzheimer’s disease psychosis trial.
• The analyst action was the clearest company-specific catalyst for the August 18, 2026 move.
• Shares rose as broader markets traded lower, indicating company-specific strength rather than market momentum.